These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 19615787)

  • 1. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
    Haj-Ali Saflo O; Hernández Guijo JM
    Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists].
    Hofmann WP; Bock H; Weber C; Tacke W; Pfaff R; Kihn R; Moog G; Kellner HU; Schöfer M; Frick B; Berg P; Rambow A; Friedrich-Rust M; Herrmann E; Sarrazin C; Zeuzem S
    Z Gastroenterol; 2006 Jan; 44(1):25-31. PubMed ID: 16397836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].
    Stahmeyer JT; Rossol S; Bert F; Abdelfattah M; Krauth C
    Z Gastroenterol; 2014 Sep; 52(9):1041-9. PubMed ID: 25075995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CLINICAL AND ECONOMIC ANALYSIS OF ALTERNATIVE SCHEMES OF ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C GENOTYPE 1 IN PATIENTS WHO DID NOT ANSWER TO THE PRIOR THERAPY, IN THE RUSSIAN FEDERATION].
    Pyadushkina EV; Avxentyeva MV; Omelyanovsky VV; Khachatryan GR
    Eksp Klin Gastroenterol; 2015; (3):55-65. PubMed ID: 26281179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire.
    Crawford B; Yeung CK; Tanaka E; Kraemer M; Leteneux C
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):765-73. PubMed ID: 23252358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C: An Eastern Perspective.
    Dan YY; Lim SG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of interferon treatment for hepatitis C.
    van Leeuwen DJ
    JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
    Koff RS
    J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
    Girardin F; Goossens N; Vernaz N; Negro F
    Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of interferon treatment for hepatitis C.
    Henley E
    JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Bernstein D
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559948
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Dore GJ; Thein HH
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559947
    [No Abstract]   [Full Text] [Related]  

  • 14. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.
    Kieran J; Bennett K; Coghlan M; Bergin C; Barry M
    Ir Med J; 2015 Jun; 108(6):166-9. PubMed ID: 26182797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.
    Shafran SD
    Can J Gastroenterol Hepatol; 2015; 29(1):46-8. PubMed ID: 25706574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'HepConomics': cost-effective, indeed, but how can we pay for it?
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
    [No Abstract]   [Full Text] [Related]  

  • 17. [Costs of modern treatment of chronic hepatitis C].
    Stiefelhagen P; Sarrazin C
    Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
    [No Abstract]   [Full Text] [Related]  

  • 18. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 19. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
    Reau NS; Jensen DM
    Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL.
    Saag MS
    Clin Infect Dis; 2015 Jul; 61(2):169-70. PubMed ID: 25778748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.